1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Shire suffers amid the end of Adderall

 
• By Simon Varcoe

Shire's second-quarter product sales were hit as expected by a heavy decline in sales of its lead product Adderall XR, after Teva Pharmaceutical Industries launched a generic version in April.

Shire's second-quarter product sales were hit as expected by a heavy decline in sales of its lead product Adderall XR, after Teva Pharmaceutical Industries launched a generic version in April.

Sales of Adderall XR (amphetamine mixed salts) slumped by 77% to $67.4 million, mainly because of a 48% decline in US prescriptions for the attention deficit hyperactivity disorder (ADHD) treatment....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapeutic Category

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 
• By Mary Jo Laffler

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 
• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.